PHS
RXDX

PFM Health Sciences’s Ignyta, Inc. RXDX Stock Holding History

PFM Health Sciences’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,820,496
Closed -$18.8M – 111
2017
Q2 		$18.8M Buy
+1,820,496
New +$14.8M 0.51% 62

Other funds holding RXDX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

PFM Health Sciences's RXDX Position: Q3 2017 in Review

PFM Health Sciences sold out of Ignyta, Inc. (RXDX) in Q3 2017, closing a stake of 1,820,496 shares — an estimated $18.8M sold.

PFM Health Sciences first reported a position in RXDX in Q2 2017 and held it in 1 quarter. The position peaked at $18.8M in Q2 2017. 120 funds tracked by Wall St. Rank hold RXDX as of Q3 2017.

  • PFM Health Sciences reported no remaining Ignyta, Inc. position as of Q3 2017 after selling out during the quarter.
  • PFM Health Sciences sold 1,820,496 Ignyta, Inc. shares in Q3 2017, an estimated $18.8M.
  • PFM Health Sciences first reported a position in Ignyta, Inc. in Q2 2017 and held it in 1 quarter.
  • PFM Health Sciences's Ignyta, Inc. position peaked at $18.8M in Q2 2017.
  • 120 funds tracked by Wall St. Rank held Ignyta, Inc. as of Q3 2017.

Based on PFM Health Sciences's 13F filing for Q3 2017, filed 14 Nov 2017.